EDUNN Pharmaceuticals

EDUNN Pharmaceuticals is an early-stage biotechnology company focused on the development of novel small molecule therapeutics for central nervous system (CNS) disorders. The company's primary research efforts center on modulating the N-methyl-D-aspartate (NMDA) receptor and Sigma-1 receptor pathways to address unmet needs in mental health and neurodegenerative diseases. Their lead programs are currently in the pre-clinical stage, targeting indications such as treatment-resistant depression and post-traumatic stress disorder. EDUNN aims to leverage its proprietary chemical library to identify candidates with improved safety profiles and rapid-acting efficacy compared to current standards of care.